Last reviewed · How we verify

Lokelma Oral Product

St George's, University of London · Phase 3 active Small molecule

Lokelma Oral Product is a Potassium binder Small molecule drug developed by St George's, University of London. It is currently in Phase 3 development for Hyperkalemia (elevated serum potassium). Also known as: placebo.

Lokelma is a potassium binder that selectively captures and removes potassium from the gastrointestinal tract to lower serum potassium levels.

Lokelma is a potassium binder that selectively captures and removes potassium from the gastrointestinal tract to lower serum potassium levels. Used for Hyperkalemia (elevated serum potassium).

At a glance

Generic nameLokelma Oral Product
Also known asplacebo
SponsorSt George's, University of London
Drug classPotassium binder
TargetPotassium ion (K+) in gastrointestinal lumen
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Lokelma (sodium zirconium cyclosilicate) is an inorganic, non-absorbed potassium binder that works in the distal colon by exchanging sodium for potassium ions, thereby reducing serum potassium concentration. The drug is not systemically absorbed and potassium is eliminated in feces, making it suitable for chronic management of hyperkalemia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lokelma Oral Product

What is Lokelma Oral Product?

Lokelma Oral Product is a Potassium binder drug developed by St George's, University of London, indicated for Hyperkalemia (elevated serum potassium).

How does Lokelma Oral Product work?

Lokelma is a potassium binder that selectively captures and removes potassium from the gastrointestinal tract to lower serum potassium levels.

What is Lokelma Oral Product used for?

Lokelma Oral Product is indicated for Hyperkalemia (elevated serum potassium).

Who makes Lokelma Oral Product?

Lokelma Oral Product is developed by St George's, University of London (see full St George's, University of London pipeline at /company/st-george-s-university-of-london).

Is Lokelma Oral Product also known as anything else?

Lokelma Oral Product is also known as placebo.

What drug class is Lokelma Oral Product in?

Lokelma Oral Product belongs to the Potassium binder class. See all Potassium binder drugs at /class/potassium-binder.

What development phase is Lokelma Oral Product in?

Lokelma Oral Product is in Phase 3.

What are the side effects of Lokelma Oral Product?

Common side effects of Lokelma Oral Product include Constipation, Nausea, Abdominal discomfort.

What does Lokelma Oral Product target?

Lokelma Oral Product targets Potassium ion (K+) in gastrointestinal lumen and is a Potassium binder.

Related